Boston Scientific Corporation $BSX Shares Acquired by Consolidated Planning Corp

Consolidated Planning Corp lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 50,313 shares of the medical equipment provider’s stock after buying an additional 1,133 shares during the quarter. Consolidated Planning Corp’s holdings in Boston Scientific were worth $5,404,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. 1248 Management LLC acquired a new position in shares of Boston Scientific during the 1st quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific during the 1st quarter valued at about $27,000. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific during the 2nd quarter valued at about $37,000. Finally, Activest Wealth Management increased its stake in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 373 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Barclays boosted their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Wells Fargo & Company boosted their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $120.67.

Boston Scientific Stock Down 1.9%

NYSE BSX opened at $95.78 on Thursday. The stock has a market cap of $141.91 billion, a PE ratio of 57.01, a P/E/G ratio of 2.35 and a beta of 0.61. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The business has a 50 day moving average price of $103.30 and a two-hundred day moving average price of $102.08. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.